Geographic variation in the second-line treatment of non-small cell lung cancer

Seminars in Oncology

Volumn 33, Issue SUPPL. 1, 2006, Pages 39-44

  Edelman, Martin J ^a   Sekine, Ikuo ^b   Tamura, Tomohide ^b   Saijo, Nagahiro ^c  

^a UNIVERSITY OF MARYLAND   (United States)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLIC ACID ANTAGONIST; GEFITINIB; IFOSFAMIDE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM; PLATINUM DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CLINICAL TRIAL; CORRELATION ANALYSIS; CYTOTOXICITY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DNA POLYMORPHISM; DOCTOR PATIENT RELATION; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; ETHNIC DIFFERENCE; EUROPEAN UNION; FEBRILE NEUTROPENIA; GEOGRAPHY; HEALTH CARE; HEALTH ECONOMICS; HUMAN; INTERSTITIAL LUNG DISEASE; JAPAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; NEUROPATHY; NORTH AMERICA; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; UNITED STATES;

EID: 32044444081     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.12.003     Document Type: Article

References (40)

1. D. Schottenfeld, J.G. Searle The etiology and epidemiology of lung cancer H.I. Pass D.P. Carbone J.D. Minna Lung Cancer Principles and Practice (ed 3). 2005 Lippincott, Williams & Wilkins Philadelphia, PA 3 24
2. W.D. Travis Pathology of lung cancer Clin Chest Med 23 2002 65 81
3. F. Shepherd, J. Dancey, R. Ramlau Prospective randomized trial of docetaxel vs. best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
4. F.V. Fossella, R. DeVore, R. Kerr Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing chemotherapy regimens J Clin Oncol 18 2000 2354 2362
5. N. Hanna, F.A. Shepherd, F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
6. J.R. Johnson, G. Williams, R. Pazdur End points and United States Food and Drug Administration approval of oncology drugs J Clin Oncol 21 2003 1404 1411
7. G. Giaccone, J.L. Gonzalez-Larriba, A.T. van Oosterom Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors Ann Oncol 15 2004 831 838
8. R. Herbst, G. Giaccone, J.H. Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer A phase III trial-INTACT2 J Clin Oncol 22 2004 785 794
9. M. Fukuoka, S. Yano, G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2003 2237 2246
10. M.G. Kris, R.B. Natale, R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer A randomized trial JAMA 290 2003 2149 2158
11. R.S. Herbst, G. Giaccone, J. Schiller Subset analysis of INTACT results for gefitinib (ZD1839) when combined with platinum based chemotherapy for advanced non-small cell lung cancer Proc Am Soc Clin Oncol 22 2003 627 abstr 2523
12. J.G. Paez, P.A. Janne, J.C. Lee EGFR mutations in lung cancer Correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
13. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2139 2159
14. M.S. Tsao, A. Sakurada, J.C. Cutz Erlotinib in lung cancer-Molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
15. N. Thatcher, A. Chang, P. Parikh Results of a phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care (BSC) in patients with advanced non-small-cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens Proc Am Assoc Cancer Res 2005 abstr LB-6
16. R. Pérez-Soler, A. Chachoua, L.A. Hammond Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 2004 3238 3247
17. F.A. Shepherd, J. Rodrigues Pereira Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
18. M.H. Cohen, G.A. Williams, R. Sridhara United States Food and Drug Administration Drug Approval summary Gefitinib (ZD1839; Iressa) tablets Clin Cancer Res 10 2004 1212 1218
19. FDA gefitinib information: Available at: http://www.fda.gov/cder/drug/ infopage/gefitinib/default.htm. accessed August 6, 2005
20. Y. Fujiwara MD reviewers' role in the new anticancer drug approval process in the newly established Japanese regulatory agency, PMDEC (Pharmaceuticals and Medical Devices Evaluation Center) Jpn J Clin Oncol 28 1998 653 656
21. T. Takano, Y. Ohe, H. Sakamoto Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2005 6829 6837
22. T. Mitsudomi, T. Kosaka, H. Endoh Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence J Clin Oncol 23 2005 2513 2520
23. H. Shigematsu, L. Lin, T. Takahashi Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 2005 339 346
24. T. Takano, Y. Ohe, M. Kusumoto Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib Lung Cancer 45 2004 93 104
25. Ministry of Health, Labour, and Welfare of Japan: Acute ILD associated with the use of gefitinib reported to Pharmaceuticals and Medical Devices Agency Japan. Available at: http://www.mhlw.go.jp/shingi/2005/01/txt/s0120-4.txt. accessed August 6, 2005
26. AstraZeneca: Results and discussion on IRESSA Tablet 250 prospective survey. Available at: http://www.mhlw.go.jp/shingi/2005/01/s0120-4.html. accessed August 6, 2005
27. T. Seto, N. Yamamoto Interstitial lung diseases (ILD) induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC) Results of a West Japan Thoracic Oncology Group (WJTOG) epidemiological survey Proc Am Soc Clin Oncol 22 2004 632s abstr 7064
28. K. Kataoka, H. Taniguchi, Y. Hasegawa Interstitial lung disease associated with gefitinib Respir Med 2005 Epub ahead of print
29. K. Ariyoshi, S. Nakajima, K. Nagao Phase II trial of weekly RP56976 in patients with non-small cell lung cancer and advanced or recurrent breast cancer 2004 Presented at the Second Annual Meeting of the Japanese Society of Medical Oncology, Tokyo, Japan, March 12-14
30. E. Esteban, L. Gonzalez de Sande, Y. Fernandez Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy Ann Oncol 14 2003 1640 1647
31. R. Gervais, A. Ducolone, J.L. Breton Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) Ann Oncol 16 2005 90 96
32. C. Gridelli, C. Gallo, M. Di Maio A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer The DISTAL 01 study Br J Cancer 91 2004 1996 2004
33. R.C. Lilenbaum, M.A. Schwartz, L. Seigel Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma Cancer 92 2001 2158 2163
34. D.R. Gandara, Y. Ohe, K. Kubota Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer A model for prospective comparison of cooperative group trials Proc Am Soc Clin Oncol 22 2004 618s abstr 7007
35. S. Marsh, M.M. Ameyaw, J. Githang'a Novel thymidylate synthase enhancer region alleles in African populations Hum Mutat 16 2000 528
36. Y. Shintani, M. Ohta, H. Hirabayashi New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction Int J Cancer 104 2003 790 795
37. T. Nakagawa, Y. Otake, K. Yanagihara Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC) Lung Cancer 43 2004 145 149
38. C.L. Huang, H. Yokomise, S. Kobayashi Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy Int J Oncol 17 2000 47 54
39. D. Giachino, P. Ghio, S. Regazzoni Pharmacogenetics studies in patients with advanced lung cancer Prognostic value of the thymidylate synthase 2R/3R polymorphism and predictivity of NER factor XPD K751Q and XRCC1 R399Q polymorphisms following platinum based chemotherapy Lung Cancer 49 suppl 2 2005 S69 abstr PD-010
40. Y. Nishiwaki, S. Yano, T. Tamura Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study of gefitinib Gan To Kagaku Ryoho 31 2004 567 573